101 related articles for article (PubMed ID: 1967410)
1. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure.
Kahn JC; Patey M; Dubois-Rande JL; Merlet P; Castaigne A; Lim-Alexandre C; Lecomte JM; Duboc D; Gros C; Schwartz JC
Lancet; 1990 Jan; 335(8681):118-9. PubMed ID: 1967410
[No Abstract] [Full Text] [Related]
2. [Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency].
Varin J; Duboc D; Weber S; Fouchard J; Schwartz JC; Muffat-Joly M; Guérin F
Arch Mal Coeur Vaiss; 1991 Oct; 84(10):1465-71. PubMed ID: 1662033
[TBL] [Abstract][Full Text] [Related]
3. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.
Dussaule JC; Grangé JD; Wolf JP; Lecomte JM; Gros C; Schwartz JC; Bodin F; Ardaillou R
J Clin Endocrinol Metab; 1991 Mar; 72(3):653-9. PubMed ID: 1847706
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans.
Lecomte JM; Baumer P; Lim C; Duchier J; Cournot A; Dussaule JC; Ardaillou R; Gros C; Chaignon B; Souque A
Eur J Pharmacol; 1990 Apr; 179(1-2):65-73. PubMed ID: 2163851
[TBL] [Abstract][Full Text] [Related]
5. Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in stroke-prone spontaneously hypertensive rats.
Stasch JP; Knorr A; Wegner M; Hirth-Dietrich C
Hypertens Res; 1995 Jun; 18(2):137-43. PubMed ID: 7584920
[TBL] [Abstract][Full Text] [Related]
6. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
[TBL] [Abstract][Full Text] [Related]
7. Degradation of atrial natriuretic factor in mouse blood in vitro and in vivo: role of enkephalinase (EC 3.4.24.11).
Gros C; Souque A; Schwartz JC
Neuropeptides; 1990 Sep; 17(1):1-5. PubMed ID: 2148814
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.
Cleland JG; Swedberg K
Lancet; 1998 May; 351(9116):1657-8. PubMed ID: 9620738
[No Abstract] [Full Text] [Related]
9. [Clinical significance and therapeutic application of atrial natriuretic peptides].
Hirata Y
Nihon Naika Gakkai Zasshi; 1991 Jan; 80(1):112-8. PubMed ID: 1850778
[No Abstract] [Full Text] [Related]
10. Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure.
Solter P; Sisson D; Thomas W; Goetze L
J Pharmacol Exp Ther; 2000 Jun; 293(3):989-95. PubMed ID: 10869402
[TBL] [Abstract][Full Text] [Related]
11. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
12. Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients.
Piquard F; Richard R; Charloux A; Doutreleau S; Hannedouche T; Brandenberger G; Geny B
J Appl Physiol (1985); 2002 Aug; 93(2):569-75. PubMed ID: 12133866
[TBL] [Abstract][Full Text] [Related]
13. Acute renal effects of neutral endopeptidase inhibition in humans.
Schmitt F; Martinez F; Ikeni A; Savoiu C; Natov S; Laborde K; Lacour B; Grünfeld JP; Hannedouche T
Am J Physiol; 1994 Jul; 267(1 Pt 2):F20-7. PubMed ID: 7519405
[TBL] [Abstract][Full Text] [Related]
14. Novel selective thiol inhibitors of neutral endopeptidase containing heterocycles at P'2 position.
Norcini G; Morazzoni G; Pocchiari F; Santangelo F; Semeraro C
J Enzyme Inhib; 1997 Jun; 12(2):155-60. PubMed ID: 9247857
[No Abstract] [Full Text] [Related]
15. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
[TBL] [Abstract][Full Text] [Related]
16. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Roksnoer LC; van Veghel R; de Vries R; Garrelds IM; Bhaggoe UM; Friesema EC; Leijten FP; Poglitsch M; Domenig O; Clahsen-van Groningen MC; Hoorn EJ; Jan Danser AH; Batenburg WW
Kidney Int; 2015 Jul; 88(1):109-20. PubMed ID: 25830765
[TBL] [Abstract][Full Text] [Related]
17. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction.
Angus RM; Millar EA; Chalmers GW; Thomson NC
Am J Respir Crit Care Med; 1995 Jun; 151(6):2003-5. PubMed ID: 7767551
[TBL] [Abstract][Full Text] [Related]
18. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive activity of sinorphan.
Lefrançois P; Clerc G; Duchier J; Lim C; Lecomte JM; Gros C; Schwartz JC
Lancet; 1990 Aug; 336(8710):307-8. PubMed ID: 1973988
[No Abstract] [Full Text] [Related]
20. Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Wilkins MR
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):673-8. PubMed ID: 8224488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
